Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announced today that its revolutionary PlasmaButton- vaporization technology can now be used with the Gyrus ACMI SuperPulse- Generator platform. Together, the PlasmaButton electrode and SuperPulse Generator provide physicians and patients with a new, virtually bloodless treatment option for benign prostate hyperplasia (BPH) or enlarged prostate.

From Evident Corporation - Life Sciences 3 Dec 2010

FDA panel rejects expansion of drug label

The New York Times: A Food and Drug Administration advisory committee on Tuesday rejected a bid to change the labels of two drugs to say they can reduce the risk of prostate cancer. "If the drugs were approved for that purpose, they would be only the second class of cancer-prevention drugs on the market."

2 Dec 2010

Hybrigenics receives EUR 800,000 payment from Oseo

Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France’s innovation agency, Oseo Innovation, in 2008.

2 Dec 2010

First Edition: December 2, 2010

Today's health policy headlines include news about how the debt panel's plan would boost costs for seniors on Medicare; how parts of the GOP are making clear their positions regarding health reform "repeal and replace" strategy; and how limited health plans faced critics at a Senate hearing.

2 Dec 2010

Exposure to BPA during perinatal development impairs reproductive capacity of female offspring

Exposure to a ubiquitous environmental chemical during pregnancy may impair reproductive capacity of female offspring, according to a study published online in advance of print on December 2 in Environmental Health Perspectives. Fertility decreased over time in female mice that had been exposed during fetal and neonatal (perinatal) development to doses of bisphenol-A (BPA) that were lower than or equal to human environmental exposure levels.

2 Dec 2010

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

2 Dec 2010

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC).

2 Dec 2010

American-style diet plays a vital role in prostate cancer, researchers say

Elevated fat and cholesterol levels found in a typical American-style diet plays an important role in the growth and spread of prostate cancer, say researchers at Thomas Jefferson University's Kimmel Cancer Center.

2 Dec 2010

Finger length may predict prostate cancer

In a new study published in the British Journal of Cancer, researchers have revealed a connection between finger length and prostate cancer. It says that men whose ring fingers are longer than their index fingers are more likely to develop prostate cancer.

1 Dec 2010

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Men with long index fingers at lower risk of prostate cancer

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found.

1 Dec 2010

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

GenSpera, Inc. announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.

1 Dec 2010

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

30 Nov 2010

New tool to trace metabolism of carotenoids in human body

The University of Illinois scientists who linked eating tomatoes with a reduced risk of prostate cancer have developed a tool that will help them trace the metabolism of tomato carotenoids in the human body. And they've secured funding from the National Institutes of Health to do it.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

LCA calls for public discussion on guidance for lung cancer screening

Today, Lung Cancer Alliance (LCA) President & CEO Laurie Fenton-Ambrose said the recent breakthrough on CT screening for lung cancer is an extraordinary development in the battle against lung cancer and reiterated her call for an open and balanced public discussion on guidance for those at high risk who may be considering a scan.

25 Nov 2010

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

EDAP TMS SA, the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes. The award was presented on November 22, 2010 at a gathering of all major local economic and financial partners.

24 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

FDA panel rejects expansion of drug label

Hybrigenics receives EUR 800,000 payment from Oseo

First Edition: December 2, 2010

Exposure to BPA during perinatal development impairs reproductive capacity of female offspring

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

American-style diet plays a vital role in prostate cancer, researchers say

Finger length may predict prostate cancer

Debiopharm recognised with European Biopharmaceuticals company of the year award

Active surveillance improves quality of life in low-risk prostate cancer patients

Men with long index fingers at lower risk of prostate cancer

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

New tool to trace metabolism of carotenoids in human body

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

LCA calls for public discussion on guidance for lung cancer screening

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in